|
|
 |
|
Viewing report
|
|
|
|
Healthcare Review: Cancer - September 2002
Datamonitor, Feb 2002
The Cancer Review brings you the latest news, analysis and research in the cancer industry. It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.Strategic insight into the future shape of cancer companies and marketsThe most significant cancer industry news compiled into one monthly updateExpert analysis into the implications of the month's important cancer industry eventsInsight into the future shape of the market for players at all levelsAll the month's major cancer stories in headline and summary formOut of the dozens of topics covered in this month's review, the most important include:* Japan became the first country to approve AstraZeneca's Iressa for the treatment of inoperable or recurrent non-small cell lung cancer. Iressa is the first in a new class of anti-cancer drugs, known as EGF receptor inhibitors.* Five non-profitable UK biotech companies may be considering a merger, creating a new cancer player capable of competing against the majors. But a more gradual consolidation effort might suit the biotechs betterNot only keeps you updated about industry events - it also gives you opinion and insightDraws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest eventsProvides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues
Customers who bought this item also bought
Prostate Cancer Opinion Leader Forum, 2002
Healthcare Review: Cancer - October 2002
Immunotherapy in Oncology: Gaining Momentum
The Asian Cancer Market Outlook to 2010
Cancer Therapeutics Markets
Drugs of Tomorrow 2002: Colorectal Cancer
Drugs of Tommorow 2002: Breast Cancer
The Eastern European Cancer Market Outlook to 2010
|
|
|
|
